NCT07298083Recruiting
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Source: ClinicalTrials.gov · Last updated 18 Sept 2026
Brief summary (registry, in English)
The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 17 Dec 2025
- Start date
- 2 Apr 2026
- Primary completion date
- 30 Apr 2030
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT07298083
What you commit to
- Study type: Observational
- Planned participants: 60
- From 2 Apr 2026 to the primary completion date, 30 Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are pregnant and undergoing surgery for MPNST are not eligible.
Other illness
- Adult patients with cognitive impairment requiring a legally authorized representative for consent.
Age
- Patients under age 1 and neonates.
Who the study is looking for
- This study will enroll approximately 60 participants diagnosed with either MPNST or neurofibroma who are undergoing surgical resection of an MPNST or neurofibroma as part of their standard of care.
- Age ≥ 1 years. Individuals younger than 18 years old will be included. For patients of age \< 18 years, both parents' signatures will be requested.
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.
- Recurrent or primary disease.
- Patients who are \> 18 years should have the ability to understand and the willingness to sign a written informed consent document.
- English and non-English speaking patients.
Age in the registry: 1 year to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Texas M. D. Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.